ERBB2 and neoplasm: Vaccination of breast and ovarian cancer patients with HER-2/neu peptide-based vaccines supplemented with GM-CCSF adjuvant treatment over a six-month period increased the precursor frequency of HER-2/neu-specific T cells that were capable of secreting IFN-γ in response to tumour and directly lyse HER-2/neu expressing tumors [67].